Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.

NCT01561313 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AbbVie (prior sponsor, Abbott)